Ticker > Company >

Guj. Themis Biosyn share price

Gujarat Themis Biosyn Ltd.

  91.37 K   746   85 NSE: GUJTHEMIS BSE: 506879 SECTOR: Pharmaceuticals & Drugs

387.70
-1.55 (-0.40%)
BSE: 13 Nov 04:01 PM

Price Summary

Today's High

₹ 391.9

Today's Low

₹ 381

52 Week High

₹ 469.9

52 Week Low

₹ 225.75

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 5045.98 Cr.

Enterprise Value

₹ 5199.76 Cr.

No. of Shares

13.02 Cr.

P/E

103.64

P/B

4.81

Face Value

₹ 1

Div. Yield

0.17 %

Book Value (TTM)

₹  80.59

CASH

₹ 6.09 Cr.

DEBT

₹ 159.87 Cr.

Promoter Holding

59.33 %

EPS (TTM)

₹  3.74

Sales Growth

9.96%

ROE

17.41 %

ROCE

18.16%

Profit Growth

-4.29 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Gujarat Themis Biosyn Ltd.

Rifamycin-S Lovastatin

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.96%
3 Year3.77%
5 Year12.86%

Profit Growth

1 Year-4.29%
3 Year-6.96%
5 Year9.12%

ROE%

1 Year17.41%
3 Year24.29%
5 Year33.83%

ROCE %

1 Year18.16%
3 Year30.35%
5 Year44.09%

Debt/Equity

0.5555

Price to Cash Flow

103.45

Interest Cover Ratio

17.1849

CFO/PAT (5 Yr. Avg.)

1.10772126237367

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2026 59.33 0.00
Jun 2026 70.86 5.44
Mar 2026 70.86 5.44
Dec 2025 70.86 4.49
Sep 2025 70.86 3.30
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 24.2862666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 30.3467666666667% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 17.1849.
  • The Company has been maintaining an effective average operating margins of 47.65154% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -345.4557 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.10772126237367.
  • The company has a high promoter holding of 59.33%.

 Limitations

  • The company has shown a poor profit growth of -6.96418549211243% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.77300470574622% for the Past 3 years.
  • The company is trading at a high PE of 103.64.
  • The company is trading at a high EV/EBITDA of 61.6372.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 35.87 42.35 43.37 44.23 43.79
Total Expenditure 21.95 21.41 22.06 24.87 23
Operating Profit 13.92 20.94 21.31 19.36 20.79
Other Income 0.27 0.82 0.42 0.92 0.13
Interest 0.04 0.04 0.96 1.91 1.79
Depreciation 2.03 2.96 3.89 4.04 3.97
Exceptional Items 0 0 0 0 0
Profit Before Tax 12.12 18.76 16.87 14.34 15.17
Tax 3.06 4.5 4.41 3.45 4.1
Profit After Tax 9.06 14.27 12.46 10.89 11.07
Adjusted EPS (Rs) 0.83 1.31 1.14 1 1.02

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 114.85 148.39 169.82 150.8 165.82
Total Expenditure 56.81 74.76 91.09 81.96 89.41
Operating Profit 58.05 73.63 78.73 68.84 76.42
Other Income 4.05 6.59 4.37 2.43 2.43
Interest 0.83 0.18 0.23 0.36 3.84
Depreciation 2.23 2.58 3.54 5.37 12.92
Exceptional Items 0 0 0 0 0
Profit Before Tax 59.03 77.46 79.33 65.54 62.09
Tax 15.41 19.5 20.17 16.77 15.41
Net Profit 43.62 57.97 59.16 48.77 46.68
Adjusted EPS (Rs.) 4 5.32 5.43 4.48 4.28

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 7.26 7.26 7.26 10.9 10.9
Total Reserves 96.06 141.88 194.11 237.49 276.87
Borrowings 0 0 0 29.64 128.06
Other N/C liabilities 2.02 1.9 3.58 2.73 8.45
Current liabilities 31.67 35.7 36.2 37.26 89.8
Total Liabilities 137.02 186.75 241.15 318.01 514.07
Assets
Net Block 19.43 32.66 38.02 41.29 288.98
Capital WIP 12.7 20.59 91.22 184.41 121.13
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 2.77 9.81 9.92 22.26 4.49
Other N/C Assets 9.21 41.53 34.39 1.39 0.04
Current Assets 92.9 82.15 67.6 68.67 99.43
Total Assets 137.02 186.75 241.15 318.01 514.07
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 59.03 77.46 79.33 65.54 62.09
Adjustment 0.15 -2.45 0.46 5.09 15.22
Changes in Assets & Liabilities -4.36 -15.11 4.19 36.88 -17.88
Tax Paid -14.52 -20.42 -19.78 -16.49 -10.65
Operating Cash Flow 40.31 39.48 64.21 91.03 48.78
Investing Cash Flow -29.83 -20.41 -55.21 -111.82 -172.28
Financing Cash Flow -14 -13.27 -8.59 26.01 114.93
Net Cash Flow -3.51 5.79 0.41 5.22 -8.57

Corporate Actions

Investors Details

PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
promoters 70.86 70.86 70.86 70.86 59.33
anay rupen choksi 0.02 0.02 0.02 0.02 0.02
dinesh shantilal patel, j... - - - 0.61 0.51
nysha rupen choksi 0.02 0.02 0.02 0.02 0.02
pharmaceutical business g... 47.02 47.02 47.02 47.02 38.97
sachin dinesh patel 0.05 0.05 - 2.29 2.32
themis medicare limited 23.19 23.19 23.19 20.90 17.50
vividhmargi trust (truste... - - 0.61 - -
dinesh shantilal patel 0.03 0.03 - - -
jayshree d patel 0.49 0.49 - - -
reena s patel 0.04 0.04 - - -
PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
investors 29.14 29.14 29.14 29.14 40.67
ayushmat ltd 1.12 1.12 1.12 1.12 2.55
bank of india flexi cap f... - - - - 1.63
kotak mahindra life insur... - - - - 2.17
llp 0.65 0.63 0.53 0.22 0.04
quant mutual fund - quant... 1.15 1.15 1.15 1.15 7.47

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit SMERA
Credit SMERA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q2FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY26
Presentation Q4FY24
Presentation Q4FY22
Presentation Q3FY24
Presentation Q3FY22
Presentation Q2FY22
Presentation Q1FY25
Presentation Q1FY21
Presentation H1FY24

Company News

Gujarat Themis Biosyn informs about acquisition 18 Sep, 12:58 PM Gujarat Themis Biosyn gains on raising Rs 585 crore through NCDs 17 Sep, 11:50 AM Gujarat Themis Biosyn raises Rs 585 crore through NCDs 17 Sep, 11:42 AM Gujarat Themis Biosyn gets nod to raise Rs 585 crore via NCDs 11 Sep, 12:59 PM Gujarat Themis Biosyn informs about board meeting outcome 26 Aug, 10:32 AM Guj. Themis Biosyn - Quaterly Results 8 Aug, 12:00 AM Gujarat Themis Biosyn informs about disclosure 5 Aug, 11:54 AM Gujarat Themis Biosyn informs about SAST disclosure 21 Jul, 3:31 PM Gujarat Themis Biosyn informs about disclosure 17 Jul, 12:59 PM Gujarat Themis Biosyn informs about disclosure 17 Jul, 12:44 PM Gujarat Themis Biosyn informs about disclosure 15 Jul, 10:52 AM Gujarat Themis Biosyn informs about disclosures 4 Jul, 2:38 PM Gujarat Themis Biosyn informs about disclosures 4 Jul, 2:27 PM Gujarat Themis Biosyn informs about disclosures 2 Jul, 12:22 PM Gujarat Themis Biosyn informs about disclosure 2 Jul, 10:11 AM Gujarat Themis Biosyn informs about notice of postal ballot 9 Jun, 10:32 AM Gujarat Themis Biosyn informs about outcome of postal ballot 5 Jun, 1:15 PM Guj. Themis Biosyn - Quaterly Results 26 May, 12:00 AM Gujarat Themis Biosyn signs definitive agreement to acquire MicroBiopharm Japan Co 23 May, 10:48 AM Gujarat Themis Biosyn soars on signing pact to acquire Sanofi’s anti TB, anti-infective brands 24 Apr, 9:25 AM Gujarat Themis Biosyn to acquire Sanofi’s anti TB, anti-infective brands 24 Apr, 9:11 AM Gujarat Themis Biosy informs about newspaper publication 19 Mar, 11:25 AM Guj. Themis Biosyn - Quaterly Results 6 Feb, 12:00 AM Gujarat Themis Biosyn informs about disclosure 20 Jan, 11:52 AM Gujarat Themis Biosyn informs about disclosure 3 Jan, 10:41 AM Guj. Themis Biosyn - Quaterly Results 11 Nov, 12:00 AM Gujarat Themis Biosyn starts production in Fermentation Block at Vapi facility 18 Oct, 5:29 PM Gujarat Themis Biosyn informs about commencement of commercial production 18 Oct, 11:17 AM Gujarat Themis Biosyn informs about clarification 23 Sep, 3:05 PM Guj. Themis Biosyn - Quaterly Results 1 Aug, 1:44 PM Guj. Themis Biosyn - Quaterly Results 1 Aug, 1:44 PM Guj. Themis Biosyn - Quaterly Results 1 Aug, 1:44 PM Guj. Themis Biosyn - Quaterly Results 20 May, 8:36 PM Guj. Themis Biosyn - Quaterly Results 20 May, 8:36 PM Gujarat Themis Biosyn starts commercial production in newly set up API plant in Gujarat 6 May, 3:45 PM Guj. Themis Biosyn - Quaterly Results 14 Feb, 1:17 PM Guj. Themis Biosyn - Quaterly Results 14 Feb, 1:17 PM Guj. Themis Biosyn - Quaterly Results 14 Feb, 1:17 PM Guj. Themis Biosyn - Quaterly Results 25 Oct, 1:32 PM Guj. Themis Biosyn - Quaterly Results 25 Oct, 1:32 PM Guj. Themis Biosyn - Quaterly Results 25 Oct, 1:32 PM Gujarat Themis Biosyn informs about investors presentation 27 Jul, 11:44 AM Guj. Themis Biosyn - Quaterly Results 26 Jul, 2:16 PM Guj. Themis Biosyn - Quaterly Results 26 Jul, 2:16 PM Guj. Themis Biosyn - Quaterly Results 26 Jul, 2:16 PM Gujarat Themis Biosyn informs about AGM proceedings 23 Jul, 5:26 PM Gujarat Themis Biosyn informs about newspaper advertisement 28 Jun, 2:38 PM Gujarat Themis Biosyn informs about loss off share certificate 29 May, 2:33 PM Guj. Themis Biosyn - Quaterly Results 14 May, 3:18 PM Guj. Themis Biosyn - Quaterly Results 14 May, 3:18 PM

Guj. Themis Biosyn Stock Price Analysis and Quick Research Report. Is Guj. Themis Biosyn an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Guj. Themis Biosyn. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Guj. Themis Biosyn has a PE ratio of 103.894888793841 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Guj. Themis Biosyn has ROA of 11.2204% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Guj. Themis Biosyn has a Current ratio of 1.1073.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Guj. Themis Biosyn has a ROE of 17.4136%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Guj. Themis Biosyn has a Debt to Equity ratio of 0.5555 which means that the company has low proportion of debt in its capital.

  • Sales growth: Guj. Themis Biosyn has reported revenue growth of 9.9621% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Guj. Themis Biosyn for the current financial year is 46.0838316564429%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Guj. Themis Biosyn is Rs 0.67 and the yield is 0.1721%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Guj. Themis Biosyn is Rs 3.7408. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Guj. Themis Biosyn in Ticker for free. Also, one can get the intrinsic value of Guj. Themis Biosyn by using Valuation Calculators, which are available with a Finology ONE subscription. 

Guj. Themis Biosyn FAQs

Q1. What is Guj. Themis Biosyn share price today?
Ans: The current share price of Guj. Themis Biosyn is Rs 388.65.

Q2. What is the market capitalisation of Guj. Themis Biosyn?
Ans: Guj. Themis Biosyn has a market capitalisation of Rs 5058.346014825 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Guj. Themis Biosyn?
Ans: The PE ratio of Guj. Themis Biosyn is 103.894888793841 and the P/B ratio of Guj. Themis Biosyn is 4.8228219433745, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Guj. Themis Biosyn share?
Ans: The 52-week high share price of Guj. Themis Biosyn is Rs 470.05, and the 52-week low share price of Guj. Themis Biosyn is Rs 225.05.

Q5. Does Guj. Themis Biosyn pay dividends?
Ans: Currently, Guj. Themis Biosyn pays dividends. Dividend yield of Guj. Themis Biosyn is around 0.1721%.

Q6. What are the face value and book value of Guj. Themis Biosyn shares?
Ans: The face value of Guj. Themis Biosyn shares is Rs 1, while the book value per share of Guj. Themis Biosyn is around Rs 80.5856. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Guj. Themis Biosyn?
Ans: Guj. Themis Biosyn has a total debt of Rs 159.8656 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Guj. Themis Biosyn?
Ans: The ROE of Guj. Themis Biosyn is 17.4136% and ROCE of Guj. Themis Biosyn is 18.1639%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Guj. Themis Biosyn a good buy for the long term?
Ans: The Guj. Themis Biosyn long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Guj. Themis Biosyn undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Guj. Themis Biosyn appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Guj. Themis Biosyn’s financials?
Ans: You can review Guj. Themis Biosyn’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Guj. Themis Biosyn
X